Virawudh Soontornniyomkij1,2, Anya Umlauf1, Benchawanna Soontornniyomkij2, Ben Gouaux1, Ronald J Ellis1,3, Andrew J Levine4, David J Moore1,2, Scott L Letendre1,5. 1. HIV Neurobehavioral Research Program. 2. Department of Psychiatry. 3. Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla. 4. Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles. 5. Department of Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA.
Abstract
OBJECTIVE: Antiretroviral therapy (ART) is currently recommended for all persons living with HIV (PLWH), regardless of their CD4 T-cell count, and should be continued throughout life. Nonetheless, vigilance of the safety of ART, including its neurotoxicity, must continue. We hypothesized that use of certain ART drugs might be associated with aging-related cerebral degenerative changes among PLWH. DESIGN: Clinicopathological study of PLWH who were using ART drugs at the last clinical assessment. METHODS: Using multivariable logistic regression, we tested associations between use of each specific ART drug (with reference to use of other ART drugs) and cerebral degenerative changes including neuronal phospho-tau lesions, β-amyloid plaque deposition, microgliosis, and astrogliosis in the frontal cortex and putamen (immunohistochemistry), as well as cerebral small vessel disease (CSVD) in the forebrain white matter (standard histopathology), with relevant covariates being taken into account. The Bonferroni adjustment was applied. RESULTS: Darunavir use was associated with higher likelihood of neuronal phospho-tau lesions in the putamen [odds ratio (OR) 15.33, n = 93, P = 0.005]. Ritonavir use was associated with marked microgliosis in the putamen (OR 4.96, n = 101, P = 0.023). On the other hand, use of tenofovir disoproxil fumarate was associated with lower likelihood of β-amyloid plaque deposition in the frontal cortex (OR 0.13, n = 102, P = 0.012). There was a trend toward an association between emtricitabine use and CSVD (OR 13.64, n = 75, P = 0.099). CONCLUSION: Our findings suggest that PLWH treated with darunavir and ritonavir may be at increased risk of aging-related cerebral degenerative changes.
OBJECTIVE: Antiretroviral therapy (ART) is currently recommended for all persons living with HIV (PLWH), regardless of their CD4 T-cell count, and should be continued throughout life. Nonetheless, vigilance of the safety of ART, including its neurotoxicity, must continue. We hypothesized that use of certain ART drugs might be associated with aging-related cerebral degenerative changes among PLWH. DESIGN: Clinicopathological study of PLWH who were using ART drugs at the last clinical assessment. METHODS: Using multivariable logistic regression, we tested associations between use of each specific ART drug (with reference to use of other ART drugs) and cerebral degenerative changes including neuronal phospho-tau lesions, β-amyloid plaque deposition, microgliosis, and astrogliosis in the frontal cortex and putamen (immunohistochemistry), as well as cerebral small vessel disease (CSVD) in the forebrain white matter (standard histopathology), with relevant covariates being taken into account. The Bonferroni adjustment was applied. RESULTS:Darunavir use was associated with higher likelihood of neuronal phospho-tau lesions in the putamen [odds ratio (OR) 15.33, n = 93, P = 0.005]. Ritonavir use was associated with marked microgliosis in the putamen (OR 4.96, n = 101, P = 0.023). On the other hand, use of tenofovir disoproxil fumarate was associated with lower likelihood of β-amyloid plaque deposition in the frontal cortex (OR 0.13, n = 102, P = 0.012). There was a trend toward an association between emtricitabine use and CSVD (OR 13.64, n = 75, P = 0.099). CONCLUSION: Our findings suggest that PLWH treated with darunavir and ritonavir may be at increased risk of aging-related cerebral degenerative changes.
Authors: Dian-sheng Zhong; Xiang-huai Lu; Brian S Conklin; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: Mona A Mohamed; Peter B Barker; Richard L Skolasky; Ola A Selnes; Richard T Moxley; Martin G Pomper; Ned C Sacktor Journal: Magn Reson Imaging Date: 2010-08-04 Impact factor: 2.546
Authors: Douglas A Green; Eliezer Masliah; Harry V Vinters; Pouneh Beizai; David J Moore; Cristian L Achim Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Brian S Conklin; Weiping Fu; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen Journal: Cardiovasc Res Date: 2004-07-01 Impact factor: 10.787
Authors: Alejandra Borjabad; Susan Morgello; Wei Chao; Seon-Young Kim; Andrew I Brooks; Jacinta Murray; Mary Jane Potash; David J Volsky Journal: PLoS Pathog Date: 2011-09-01 Impact factor: 6.823
Authors: Irina Alafuzoff; Thomas Arzberger; Safa Al-Sarraj; Istvan Bodi; Nenad Bogdanovic; Heiko Braak; Orso Bugiani; Kelly Del-Tredici; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Paul Ince; Wouter Kamphorst; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; Sergey Larionov; David Meyronet; Camelia Monoranu; Piero Parchi; Efstratios Patsouris; Wolfgang Roggendorf; Danielle Seilhean; Fabrizio Tagliavini; Christine Stadelmann; Nathalie Streichenberger; Dietmar R Thal; Stephen B Wharton; Hans Kretzschmar Journal: Brain Pathol Date: 2008-03-26 Impact factor: 6.508
Authors: Isaac H Solomon; Sukrutha Chettimada; Vikas Misra; David R Lorenz; Robert J Gorelick; Benjamin B Gelman; Susan Morgello; Dana Gabuzda Journal: Mol Neurobiol Date: 2019-11-05 Impact factor: 5.590
Authors: Jane A O'Halloran; Sarah A Cooley; Jeremy F Strain; Anna Boerwinkle; Robert Paul; Rachel M Presti; Beau M Ances Journal: AIDS Date: 2019-07-15 Impact factor: 4.177
Authors: Andrea Calcagno; Luigi Celani; Mattia Trunfio; Giancarlo Orofino; Daniele Imperiale; Cristiana Atzori; Vincenzo Arena; Gabriella d'Ettorre; Giovanni Guaraldi; Magnus Gisslen; Giovanni Di Perri Journal: Neurol Clin Pract Date: 2021-10
Authors: Mattia Trunfio; Cristiana Atzori; Marta Pasquero; Alessandro Di Stefano; Daniela Vai; Marco Nigra; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno Journal: Viruses Date: 2022-04-04 Impact factor: 5.818